Related Experiment Videos
Ridogrel enemas in distal ulcerative colitis.
J J Auwerda1, F J Zijlstra, C J Tak
1Department of Internal Medicine and Pathology, Ikazia Hospital, Montessoriweg 1, 3083 AN Rotterdam, The Netherlands. auwerda@mdl.azr.nl
Summary
Ridogrel enemas significantly reduced mucosal thromboxane B2 (TxB2) levels in patients with ulcerative colitis. While some patients showed disease improvement, other inflammatory markers remained unchanged, suggesting a targeted effect of Ridogrel.
Area of Science:
- Gastroenterology
- Inflammation Research
- Pharmacology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Current treatments for UC have limitations and side effects.
- Targeting specific inflammatory mediators may offer new therapeutic avenues.
Purpose of the Study:
- To assess the efficacy of Ridogrel enemas in treating active left-sided ulcerative colitis.
- To evaluate the impact of Ridogrel on disease activity and mucosal inflammatory mediators.
Main Methods:
- An open-label, non-placebo-controlled pilot study involving eleven UC patients.
- Patients received Ridogrel enemas (300 mg/40 ml daily) for four weeks.
- Disease activity scores and mucosal concentrations of TxB2, PGE2, IL-6, and TNF-alpha were measured before and after treatment.
Main Results:
- Ten out of eleven patients tolerated Ridogrel enemas well.
- A significant decrease in mucosal thromboxane B2 (TxB2) concentration was observed in all patients.
- Prostaglandin E2 (PGE2), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha) levels remained unaltered.
- Five patients experienced a decrease in disease score, but clinical improvement did not consistently correlate with endoscopic or histological changes.
Conclusions:
- Ridogrel enemas demonstrated a selective reduction in mucosal TxB2 concentration in UC patients.
- This finding suggests a potential targeted anti-inflammatory mechanism for Ridogrel in ulcerative colitis.